Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform

Latest


Applying Small Molecule Agility to Biologics
0:40
Applying Small Molecule Agility to Biologics
an hour ago
by
Michael Christel(+2 more)
The Future of Antibody Manufacturing
0:39
The Future of Antibody Manufacturing
21 hours ago
by
Michael Christel(+2 more)
How FDA is Changing Rare Disease Drug Approvals
1:00
How FDA is Changing Rare Disease Drug Approvals
a day ago
by
Emily Schoenthaler(+1 more)
FDA Investigates Cancer Risk in Novartis' Gene Therapy
1:07
FDA Investigates Cancer Risk in Novartis' Gene Therapy
5 days ago
by
Emily Schoenthaler
FDA Grants Accelerated Approval for New Cancer Treatment
1:28
FDA Grants Accelerated Approval for New Cancer Treatment
8 days ago
by
Emily Schoenthaler
A Potential Breakthrough for Huntington's Disease
1:56
A Potential Breakthrough for Huntington's Disease
13 days ago
by
Emily Schoenthaler
Why Developability Matters in Drug Manufacturing
0:39
Why Developability Matters in Drug Manufacturing
14 days ago
by
Emily Schoenthaler
AAPS 2026 PharmSci 360: A Video Recap
1:10
AAPS 2026 PharmSci 360: A Video Recap
18 days ago
by
Feliza Mirasol(+2 more)
A Potential Game Changer for At-Home Medical Treatment
1:23
A Potential Game Changer for At-Home Medical Treatment
18 days ago
by
Emily Schoenthaler(+1 more)
The Evolution of Cold Chain: From Preservation to Prediction
0:51
The Evolution of Cold Chain: From Preservation to Prediction
18 days ago
by
Feliza Mirasol(+3 more)

Analytics for Bispecific Antibody Product Release

Planning the analytical strategy for product release should be started as early as possible to ensure product quality and regulatory success.

Analytics for Bispecific Antibody Product Release

FAQ: What You Need to Know About Analytical Method Validation

We answer readers’ top questions on limit of blank, limit of detection, limit of quantitation, acceptance criteria, and equivalence testing in analytical method validation.

FAQ: What You Need to Know About Analytical Method Validation

Digital Standards Aim to Modernize Quality Assurance Without Compromising Confidence

As quality control labs move toward more connected, data-driven operations, digital technologies must be adopted in a way that upholds patient safety.

Digital Standards Aim to Modernize Quality Assurance Without Compromising Confidence

What FDA's AI Warning Letter Tells Us About GMP Accountability

An FDA warning letter to Purolea Cosmetics Lab shows that AI-assisted drafting can support documentation work only when the resulting document is subject to quality-system controls.

What FDA's AI Warning Letter Tells Us About GMP Accountability

Expedited Regulatory Pathways for Biologics

This episode of the BioPharm Drug Digest will examine strategic triggers that have thus far won expedited regulatory review for biologics in development.

Expedited Regulatory Pathways for Biologics


All News

FDA issues a complete response letter for Summit Therapeutics’ PD-1/VEGF bispecific ivonescimab in EGFR-mutated non-small cell lung cancer, approves Roche’s obinutuzumab (Gazyva) for primary membranous nephropathy, and approves AstraZeneca’s nanobody C5 inhibitor gefurulimab (Klygefa) for generalized myasthenia gravis.

FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.